Literature DB >> 10171907

Reaping maximum benefits from minimally invasive surgery.

J D Seus1, T Wood.   

Abstract

A study conducted by Deloitte & Touche examined the use of minimally invasive surgery (MIS)--specifically laparoscopic cholecystectomy, laparoscopically assisted vaginal hysterectomy laparoscopic inguinal hernia repair and thoracoscopic wedge resection--at nine U.S. hospitals. From a total hospital cost perspective, two procedures studied reduce hospital costs, one is a breakeven and one increases hospital costs. In addition, with MIS there is a major shift in resource consumption from nursing care units to the operating room. Best practices, defined as most efficient staffing levels, operative times, lengths of hospital stay and other treatment characteristics practiced at the study hospitals, were also identified. Hospitals can maximize their return on MIS by providing ample training to surgical and processing staff, standardizing on equipment, wisely choosing when to use custom kits, block scheduling for MIS and incorporating MIS into the hospital's strategic plan.

Entities:  

Mesh:

Year:  1994        PMID: 10171907

Source DB:  PubMed          Journal:  J Healthc Mater Manage        ISSN: 0889-2482


  3 in total

1.  The feasibility of introducing advanced minimally invasive surgery into surgical practice.

Authors:  Daniel W Birch; Monali Misra; Forough Farrokhyar
Journal:  Can J Surg       Date:  2007-08       Impact factor: 2.089

2.  Canadian consensus conference on the development of training and practice standards in advanced minimally invasive surgery: Edmonton, Alta., Jun. 1, 2007.

Authors:  Daniel W Birch; H Jaap Bonjer; Claire Crossley; Gayle Burnett; Chris de Gara; Anthony Gomes; John Hagen; Angus G Maciver; C Dale Mercer; O Neely Panton; Chris M Schlachta; Andy J Smith; Garth L Warnock
Journal:  Can J Surg       Date:  2009-08       Impact factor: 2.089

3.  Surgical packages for laparoscopic surgery.

Authors:  K Bhattacharya
Journal:  J Minim Access Surg       Date:  2005-06       Impact factor: 1.407

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.